Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: A therapeutic strategy for parkinson's disease

Molecular Therapy

Volumn 18, Issue 8, 2010, Pages 1536-1544

  Biju, Kc ^a   Zhou, Qing ^a   Li, Guiming ^a   Imam, Syed Z ^a,b   Roberts, James L ^a,b   Morgan, William W ^a,b   Clark, Robert A ^a,b   Li, Senlin ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; CORPUS STRIATUM; DEGENERATIVE DISEASE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EX VIVO GENE TRANSFER; FLOW CYTOMETRY; FOOD INTAKE; GENE EXPRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MOUSE; NERVE FIBER REGENERATION; NONHUMAN; OPEN FIELD TEST; OPTICAL DENSITY; PARKINSON DISEASE; PLASMID; PROMOTER REGION; STEREOLOGY; SUBSTANTIA NIGRA; WEIGHT REDUCTION;

LENTIVIRUS; MUS;

EID: 77955171756     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.107     Document Type: Article

References (50)

1. Dauer, W and Przedborski, S (2003). Parkinson's disease: mechanisms and models. Neuron 39: 889-909.
2. Ahlskog, JE and Muenter, MD (2001). Frequency of levodopa-related dyskinesias and motor fuctuations as estimated from the cumulative literature. Mov Disord 16: 448-458.
3. Obeso, JA, Grandas, F, Vaamonde, J, Luquin, MR, Artieda, J, Lera, G et al. (1989). Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 39 (11 suppl. 2): 11-19.
4. Kordower, JH, Emborg, ME, Bloch, J, Ma, SY, Chu, Y, Leventhal, L et al. (2000). Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290: 767-773.
5. Björklund, A, Rosenblad, C, Winkler, C and Kirik, D (1997). Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 4: 186-200.
6. Gash, DM, Zhang, Z, Ovadia, A, Cass, WA, Yi, A, Simmerman, L et al. (1996). Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255.
7. Ramaswamy, S, Soderstrom, KE and Kordower, JH (2009). Trophic factors therapy in Parkinson's disease. Prog Brain Res 175: 201-216.
8. Pascual, A, Hidalgo-Figueroa, M, Piruat, JI, Pintado, CO, Gómez-Díaz, R and López-Barneo, J (2008). Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11: 755-761.
9. Ling, EA and Wong, WC (1993). The origin and nature of ramifed and amoeboid microglia: a historical review and current concepts. Glia 7: 9-18.
10. Nakajima, K and Kohsaka, S (2001). Microglia: activation and their signifcance in the central nervous system. J Biochem 130: 169-175.
11. Priller, J, Flügel, A, Wehner, T, Boentert, M, Haas, CA, Prinz, M et al. (2001). Targeting gene-modifed hematopoietic cells to the central nervous system: use of green fuorescent protein uncovers microglial engraftment. Nat Med 7: 1356-1361.
12. Simard, AR, Soulet, D, Gowing, G, Julien, JP and Rivest, S (2006). Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49: 489-502.
13. Williams, AE, Lawson, LJ, Perry, VH and Fraser, H (1994). Characterization of the microglial response in murine scrapie. Neuropathol Appl Neurobiol 20: 47-55.
14. Priller, J, Prinz, M, Heikenwalder, M, Zeller, N, Schwarz, P, Heppner, FL et al. (2006). Early and rapid engraftment of bone marrow-derived microglia in scrapie. J Neurosci 26: 11753-11762.
15. Kokovay, E and Cunningham, LA (2005). Bone marrow-derived microglia contribute to the neuroinfammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol Dis 19: 471-478.
16. Malm, TM, Koistinaho, M, Pärepalo, M, Vatanen, T, Ooka, A, Karlsson, S et al. (2005). Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis 18: 134-142.
17. Stalder, AK, Ermini, F, Bondolf, L, Krenger, W, Burbach, GJ, Deller, T et al. (2005). Invasion of hematopoietic cells into the brain of amyloid precursor protein transgenic mice. J Neurosci 25: 11125-11132.
18. McMahon, EJ, Suzuki, K and Matsushima, GK (2002). Peripheral macrophage recruitment in cuprizone-induced CNS demyelination despite an intact blood-brain barrier. J Neuroimmunol 130: 32-45.
19. Rodriguez, M, Alvarez-Erviti, L, Blesa, FJ, Rodríguez-Oroz, MC, Arina, A, Melero, I et al. (2007). Bone-marrow-derived cell differentiation into microglia: a study in a progressive mouse model of Parkinson's disease. Neurobiol Dis 28: 316-325.
20. Biff, A, Capotondo, A, Fasano, S, del Carro, U, Marchesini, S, Azuma, H et al. (2006). Gene therapy of metachromatic leukodystrophy reverses neurological damage and defcits in mice. J Clin Invest 116: 3070-3082.
21. Makar, TK, Bever, CT, Singh, IS, Royal, W, Sahu, SN, Sura, TP et al. (2009). Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle. J Neuroimmunol 210: 40-51.
22. Park, KW, Eglitis, MA and Mouradian, MM (2001). Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res 40: 315-323.
23. Hoane, MR, Gulwadi, AG, Morrison, S, Hovanesian, G, Lindner, MD and Tao, W (1999). Differential in vivo effects of neurturin and glial cell-line-derived neurotrophic factor. Exp Neurol 160: 235-243.
24. Tümer, N, Scarpace, PJ, Dogan, MD, Broxson, CS, Matheny, M, Yurek, DM et al. (2006). Hypothalamic rAAV-mediated GDNF gene delivery ameliorates age-related obesity. Neurobiol Aging 27: 459-470.
25. Manfredsson, FP, Burger, C, Rising, AC, Zuobi-Hasona, K, Sullivan, LF, Lewin, AS et al. (2009). Tight Long-term dynamic doxycycline responsive nigrostriatal GDNF using a single rAAV vector. Mol Ther 17: 1857-1867.
26. Sariola, H and Saarma, M (2003). Novel functions and signalling pathways for GDNF. J Cell Sci 116 (Pt 19): 3855-3862.
27. Lang, AE and Obeso, JA (2004). Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 3: 309-316.
28. Georgievska, B, Kirik, D and Björklund, A (2004). Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time-and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24: 6437-6445.
29. Nakajima, K and Kohsaka, S (2004). Microglia: neuroprotective and neurotrophic cells in the central nervous system. Curr Drug Targets Cardiovasc Haematol Disord 4: 65-84.
30. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
31. Burt, RK, Traynor, AE, Cohen, B, Karlin, KH, Davis, FA, Stefoski, D et al. (1998). T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the frst three patients. Bone Marrow Transplant 21: 537-541.
32. Mildner, A, Schmidt, H, Nitsche, M, Merkler, D, Hanisch, UK, Mack, M et al. (2007). Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defned host conditions. Nat Neurosci 10: 1544-1553.
33. Straathof, KC, Rao, K, Eyrich, M, Hale, G, Bird, P, Berrie, E et al. (2009). Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet 374: 912-920.
34. Czechowicz, A, Kraft, D, Weissman, IL and Bhattacharya, D (2007). Effcient transplantation via antibody-based clearance of hematopoietic stem cell niches. Science 318: 1296-1299.
35. Bernheimer, H, Birkmayer, W, Hornykiewicz, O, Jellinger, K and Seitelberger, F (1973). Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455.
36. McGeer, PL, Itagaki, S, Akiyama, H and McGeer, EG (1988). Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 24: 574-576.
37. Fearnley, JM and Lees, AJ (1991). Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114 (Pt 5): 2283-2301.
38. Dunnett, SB and Björklund, A (1999). Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 (6738 suppl.): A32-A39.
39. Brooks, DJ (1998). The early diagnosis of Parkinson's disease. Ann Neurol 44 (3 suppl. 1): S10-S18.
40. Horger, BA, Nishimura, MC, Armanini, MP, Wang, LC, Poulsen, KT, Rosenblad, C et al. (1998). Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18: 4929-4937.
41. Grondin, R, Zhang, Z, Ai, Y, Ding, F, Walton, AA, Surgener, SP et al. (2008). Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys. Cell Transplant 17: 373-381.
42. Lindholm, P, Voutilainen, MH, Laurén, J, Peränen, J, Leppänen, VM, Andressoo, JO et al. (2007). Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature 448: 73-77.
43. He, W, Qiang, M, Ma, W, Valente, AJ, Quinones, MP, Wang, W et al. (2006). Development of a synthetic promoter for macrophage gene therapy. Hum Gene Ther 17: 949-959.
44. Pawliuk, R, Westerman, KA, Fabry, ME, Payen, E, Tighe, R, Bouhassira, EE et al. (2001). Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294: 2368-2371.
45. Dunnett, SB, Carter, RJ, Watts, C, Torres, EM, Mahal, A, Mangiarini, L et al. (1998). Striatal transplantation in a transgenic mouse model of Huntington's disease. Exp Neurol 154: 31-40.
46. Choi, Y, Yoon, YW, Na, HS, Kim, SH and Chung, JM (1994). Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 59: 369-376.
47. Ali, SF, David, SN, Newport, GD, Cadet, JL and Slikker, W Jr (1994). MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Synapse 18: 27-34.
48. Paxinos, G and Franklin, KBJ (2001). The Mouse Brain in Stereotaxic Coordinates, 2nd edn. Academic: San Diego, CA.
49. Mandir, AS, Przedborski, S, Jackson-Lewis, V, Wang, ZQ, Simbulan-Rosenthal, CM, Smulson, ME et al. (1999). Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci USA 96: 5774-5779.
50. West, MJ, Slomianka, L and Gundersen, HJ (1991). Unbiased stereological estimation of the total number of neurons in thesubdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.